Kim L Bennell1, David J Hunter2, Kade L Paterson3. 1. Centre for Health Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, University of Melbourne, Parkville, Victoria, 3010, Australia. k.bennell@unimelb.edu.au. 2. Institute of Bone and Joint Research, Kolling Institute and Rheumatology Department, Royal North Shore Hospital, University of Sydney, Sydney, Australia. 3. Centre for Health Exercise and Sports Medicine, Department of Physiotherapy, School of Health Sciences, University of Melbourne, Parkville, Victoria, 3010, Australia.
Abstract
PURPOSE OF REVIEW: Knee and hip osteoarthritis (OA) are major public health problems worldwide causing pain, disability and impaired quality of life. This narrative paper discusses platelet-rich plasma (PRP) as a treatment for hip and knee OA, with a focus on evidence from randomised controlled trials (RCTs). RECENT FINDINGS: Since the first RCT of PRP in 2012, there has been 15 RCTs in knee OA and three in hip OA, mostly comparing PRP to another intra-articular injection therapy, hyaluronic acid. All studies are of low to moderate methodological quality and use variable PRP protocols. In general, results showed that PRP is a safe treatment with potential to provide symptomatic benefit for OA at least in the short term (up to 12 months). Younger patients with less severe disease may be more responsive. There are no RCTs investigating the effects of PRP on OA structural changes. No definitive conclusions can be made about the effects of PRP in OA given methodological concerns and considerable heterogeneity between studies. Further high-quality research is needed to establish the clinical and cost-effectiveness of PRP, the patients most likely to benefit and the optimal PRP protocol.
PURPOSE OF REVIEW: Knee and hip osteoarthritis (OA) are major public health problems worldwide causing pain, disability and impaired quality of life. This narrative paper discusses platelet-rich plasma (PRP) as a treatment for hip and knee OA, with a focus on evidence from randomised controlled trials (RCTs). RECENT FINDINGS: Since the first RCT of PRP in 2012, there has been 15 RCTs in knee OA and three in hip OA, mostly comparing PRP to another intra-articular injection therapy, hyaluronic acid. All studies are of low to moderate methodological quality and use variable PRP protocols. In general, results showed that PRP is a safe treatment with potential to provide symptomatic benefit for OA at least in the short term (up to 12 months). Younger patients with less severe disease may be more responsive. There are no RCTs investigating the effects of PRP on OA structural changes. No definitive conclusions can be made about the effects of PRP in OA given methodological concerns and considerable heterogeneity between studies. Further high-quality research is needed to establish the clinical and cost-effectiveness of PRP, the patients most likely to benefit and the optimal PRP protocol.
Authors: W L Sibbitt; L G Kettwich; P A Band; N R Chavez-Chiang; S L DeLea; L J Haseler; A D Bankhurst Journal: Scand J Rheumatol Date: 2011-11-21 Impact factor: 3.641
Authors: Marita Cross; Emma Smith; Damian Hoy; Sandra Nolte; Ilana Ackerman; Marlene Fransen; Lisa Bridgett; Sean Williams; Francis Guillemin; Catherine L Hill; Laura L Laslett; Graeme Jones; Flavia Cicuttini; Richard Osborne; Theo Vos; Rachelle Buchbinder; Anthony Woolf; Lyn March Journal: Ann Rheum Dis Date: 2014-02-19 Impact factor: 19.103
Authors: Amanda Bezerra Gonçalves; Júlia Leme Bovo; Bruna Silva Gomes; Acácio Antonio Pigoso; Maíra Felonato; Marcelo Augusto Marretto Esquisatto; Gaspar de Jesus Lopes Filho; Fernando Russo Costa do Bomfim Journal: J Lasers Med Sci Date: 2021-10-18
Authors: Teemu V Karjalainen; Michael Silagy; Edward O'Bryan; Renea V Johnston; Sheila Cyril; Rachelle Buchbinder Journal: Cochrane Database Syst Rev Date: 2021-09-30
Authors: Kim L Bennell; Kade L Paterson; Ben R Metcalf; Vicky Duong; Jillian Eyles; Jessica Kasza; Yuanyuan Wang; Flavia Cicuttini; Rachelle Buchbinder; Andrew Forbes; Anthony Harris; Shirley P Yu; David Connell; James Linklater; Bing Hui Wang; Win Min Oo; David J Hunter Journal: JAMA Date: 2021-11-23 Impact factor: 157.335
Authors: Samuel A Cohen; Thompson Zhuang; Michelle Xiao; John B Michaud; Derek F Amanatullah; Robin N Kamal Journal: J Arthroplasty Date: 2021-06-04 Impact factor: 4.435